pazopanib + paclitaxel + lapatinib

This is a **combination regimen** of three agents: pazopanib (a multi-targeted tyrosine kinase inhibitor), paclitaxel (a microtubule inhibitor/chemotherapy), and lapatinib (a dual tyrosine kinase inhibitor targeting EGFR and HER2). Pazopanib blocks vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs), inhibiting angiogenesis. Paclitaxel stabilizes microtubules and prevents cell division. Lapatinib inhibits epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2) signaling, blocking tumor proliferation. This regimen has primarily been studied for advanced or metastatic solid tumors, especially HER2-positive breast cancer, in early-phase clinical trials. The triplet targets both tumor vasculature and tumor cell signaling to potentially overcome resistance to single-agent or doublet therapy and shows evidence of pharmacokinetic interaction (increased paclitaxel exposure) and enhanced toxicity.